Skip to main content

Table 4 Comparison of treatment interruption due to adverse events between the advanced and non-advanced idiopathic pulmonary fibrosis groups

From: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Characteristic

Total

Advanced

Non-advanced

P-value

Number of patients

105

50

55

 

Administration without dose reduction

35 (33.3)

10 (20.0)

25 (45.5)

0.006

AEs leading to transient dose reduction

5 (4.8)

0 (0.0)

5 (4.8)

0.058

AEs leading to permanent dose reduction

9 (8.6)

6 (12.0)

3 (5.5)

0.304

AEs leading to permanent discontinuation

56 (53.3)

34 (68.0)

22 (40.0)

0.004

  1. Data are presented as number (%), unless otherwise indicated
  2. AEs Adverse events